We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Complement as the enabler of carfilzomib‐induced thrombotic microangiopathy.
- Authors
Blasco, Miquel; Martínez‐Roca, Alexandra; Rodríguez‐Lobato, Luis G.; Garcia‐Herrera, Adriana; Rosiñol, Laura; Castro, Pedro; Fernández, Sara; Quintana, Luis F.; Cibeira, María T.; Bladé, Joan; Fernández de Larrea, Carlos; Tovar, Natalia; Jimenez, Raquel; Poch, Esteban; Guillen, Elena; Campistol, Josep M.; Carreras, Enric; Diaz‐Ricart, Maribel; Palomo, Marta
- Abstract
Summary: Carfilzomib has been associated with the development of thrombotic microangiopathy (TMA) in relapsed/refractory multiple myeloma patients, a severe disease with no currently available aetiological treatment. We evaluated the potential role of terminal complement pathway in four patients with carfilzomib‐induced TMA. Membrane attack complex (C5b‐9) deposition on endothelial cells in culture exposed to plasma from patients during the acute phase of the disease suggests complement overactivation as a mechanism of potential endothelial damage in three out of four patients. If confirmed in larger cohorts, C5b‐9 evaluation will allow early identification of patients who could benefit from complement blockade and treatment monitoring.
- Subjects
THROMBOTIC microangiopathies; ENDOTHELIAL cells; MULTIPLE myeloma; CELL culture; ACUTE diseases
- Publication
British Journal of Haematology, 2021, Vol 193, Issue 1, p181
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.16796